Search

Your search keyword '"Benevolo, G"' showing total 17 results
Start Over Author "Benevolo, G" Journal leukemia
17 results on '"Benevolo, G"'

1. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Author

Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, and Vannucchi, A M

Published
2017
Full Text
View/download PDF

2. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

Author

Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, and Vannucchi, A M

Published
2017
Full Text
View/download PDF

3. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

Author

Larocca, A, Bringhen, S, Petrucci, M T, Oliva, S, Falcone, A P, Caravita, T, Villani, O, Benevolo, G, Liberati, A M, Morabito, F, Montefusco, V, Passera, R, De Rosa, L, Omedé, P, Vincelli, I D, Spada, S, Carella, A M, Ponticelli, E, Derudas, D, Genuardi, M, Guglielmelli, T, Nozzoli, C, Aghemo, E, De Paoli, L, Conticello, C, Musolino, C, Offidani, M, Boccadoro, M, Sonneveld, P, and Palumbo, A

Published
2016
Full Text
View/download PDF

4. Circulating miRNA markers show promise as new prognosticators for multiple myeloma

Author

Rocci, A, Hofmeister, C C, Geyer, S, Stiff, A, Gambella, M, Cascione, L, Guan, J, Benson, D M, Efebera, Y A, Talabere, T, Dirisala, V, Smith, E M, Omedè, P, Isaia, G, De Luca, L, Rossi, D, Gentili, S, Uccello, G, Consiglio, J, Ria, R, Benevolo, G, Bringhen, S, Callea, V, Weiss, B, Ferro, A, Magarotto, V, Alder, H, Byrd, J C, Boccadoro, M, Marcucci, G, Palumbo, A, and Pichiorri, F

Published
2014
Full Text
View/download PDF

5. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

Author

Musto, P, Simeon, V, Martorelli, M C, Petrucci, M T, Cascavilla, N, Di Raimondo, F, Caravita, T, Morabito, F, Offidani, M, Olivieri, A, Benevolo, G, Mina, R, Guariglia, R, D'Arena, G, Mansueto, G, Filardi, N, Nobile, F, Levi, A, Falcone, A, Cavalli, M, Pietrantuono, G, Villani, O, Bringhen, S, Omedè, P, Lerose, R, Agnelli, L, Todoerti, K, Neri, A, Boccadoro, M, and Palumbo, A

Published
2014
Full Text
View/download PDF

6. Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients

Author

Falco, P, Cavallo, F, Larocca, A, Rossi, D, Guglielmelli, T, Rocci, A, Grasso, M, Siez, M L M, De Paoli, L, Oliva, S, Molica, S, Mina, R, Gay, F, Benevolo, G, Musto, P, Omedè, P, Freilone, R, Bringhen, S, Carella, A M, Gaidano, G, Boccadoro, M, and Palumbo, A

Published
2013
Full Text
View/download PDF

7. Lenalidomide — prednisone induction followed by lenalidomide — melphalan — prednisone consolidation and lenalidomide — prednisone maintenance in newly diagnosed elderly unfit myeloma patients

Author

Falco, P, Cavallo, F, Larocca, A, Rossi, D, Guglielmelli, T, Rocci, A, Grasso, M, Siez, M LM, De Paoli, L, Oliva, S, Molica, S, Mina, R, Gay, F, Benevolo, G, Musto, P, Omedè, P, Freilone, R, Bringhen, S, Carella, A M, Gaidano, G, Boccadoro, M, and Palumbo, A

Published
2013
Full Text
View/download PDF

8. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Author

Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., and Rambaldi, A.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Aspirin, business.industry, Hematology, Second primary cancer, Settore MED/15 - MALATTIE DEL SANGUE, Internal medicine, medicine, business, Myelopriferative neoplasms, medicine.drug
Published
2019

9. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

Author

Passamonti, F, primary, Mora, B, additional, Giorgino, T, additional, Guglielmelli, P, additional, Cazzola, M, additional, Maffioli, M, additional, Rambaldi, A, additional, Caramella, M, additional, Komrokji, R, additional, Gotlib, J, additional, Kiladjian, J J, additional, Cervantes, F, additional, Devos, T, additional, Palandri, F, additional, De Stefano, V, additional, Ruggeri, M, additional, Silver, R, additional, Benevolo, G, additional, Albano, F, additional, Caramazza, D, additional, Rumi, E, additional, Merli, M, additional, Pietra, D, additional, Casalone, R, additional, Barbui, T, additional, Pieri, L, additional, and Vannucchi, A M, additional

Published
2016
Full Text
View/download PDF

10. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

Author

Musto, P, primary, Simeon, V, additional, Martorelli, M C, additional, Petrucci, M T, additional, Cascavilla, N, additional, Di Raimondo, F, additional, Caravita, T, additional, Morabito, F, additional, Offidani, M, additional, Olivieri, A, additional, Benevolo, G, additional, Mina, R, additional, Guariglia, R, additional, D'Arena, G, additional, Mansueto, G, additional, Filardi, N, additional, Nobile, F, additional, Levi, A, additional, Falcone, A, additional, Cavalli, M, additional, Pietrantuono, G, additional, Villani, O, additional, Bringhen, S, additional, Omedè, P, additional, Lerose, R, additional, Agnelli, L, additional, Todoerti, K, additional, Neri, A, additional, Boccadoro, M, additional, and Palumbo, A, additional

Published
2013
Full Text
View/download PDF

11. Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients

Author

Falco, P, primary, Cavallo, F, additional, Larocca, A, additional, Rossi, D, additional, Guglielmelli, T, additional, Rocci, A, additional, Grasso, M, additional, Siez, M L M, additional, De Paoli, L, additional, Oliva, S, additional, Molica, S, additional, Mina, R, additional, Gay, F, additional, Benevolo, G, additional, Musto, P, additional, Omedè, P, additional, Freilone, R, additional, Bringhen, S, additional, Carella, A M, additional, Gaidano, G, additional, Boccadoro, M, additional, and Palumbo, A, additional

Published
2012
Full Text
View/download PDF

12. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

Author

Giuseppe Pietrantuono, Giovanni D'Arena, Roberto Guariglia, F. Di Raimondo, Massimo Offidani, Paola Omedè, Attilio Olivieri, Nicola Cascavilla, Tommaso Caravita, Roberto Mina, Pellegrino Musto, Katia Todoerti, Maide Cavalli, Nunzio Filardi, Mario Boccadoro, Fortunato Morabito, Francesco Nobile, Sara Bringhen, Antonio Palumbo, Luca Agnelli, Maria Carmen Martorelli, Oreste Villani, Antonino Neri, Vittorio Simeon, G. Mansueto, A. Falcone, Giulia Benevolo, Rosa Lerose, M.T. Petrucci, Anna Levi, Musto, P, Simeon, V, Martorelli, M C, Petrucci, M T, Cascavilla, N, Di Raimondo, F, Caravita, T, Morabito, F, Offidani, M, Olivieri, A, Benevolo, G, Mina, R, Guariglia, R, D'Arena, G, Mansueto, G, Filardi, N, Nobile, F, Levi, A, Falcone, A, Cavalli, M, Pietrantuono, G, Villani, O, Bringhen, S, Omedè, P, Lerose, R, Agnelli, L, Todoerti, K, Neri, A, Boccadoro, M, and Palumbo, A

Subjects
Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Newly diagnosed, Dexamethasone, Leukemia, Plasma Cell, Internal medicine, medicine, Humans, Lenalidomide, Aged, Plasma cell leukemia, Aged, 80 and over, Chemotherapy, business.industry, Low dose, Hematology, Middle Aged, medicine.disease, Surgery, Thalidomide, Female, business, medicine.drug
Published
2013

13. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.

Author

Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, De Stefano V, Caramella M, Salmoiraghi S, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Ruggeri M, Silver RT, Albano F, Benevolo G, Ross DM, Della Porta MG, Devos T, Rotunno G, Komrokji RS, Casetti IC, Merli M, Brociner M, Caramazza D, Auteri G, Barbui T, Cattaneo D, Bertù L, Arcaini L, Vannucchi AM, and Passamonti F

Subjects
Humans, Hydroxyurea therapeutic use, Janus Kinase Inhibitors, Polycythemia Vera complications, Polycythemia Vera therapy, Primary Myelofibrosis etiology, Primary Myelofibrosis therapy, Thrombocythemia, Essential complications, Thrombosis etiology
Abstract

Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events (TEs). Predisposing factors have been identified in essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (primary MF, PMF), while yet not recognized in post PV/ET-MF (known as secondary MF, SMF). Within the 1258 SMF of the MYSEC (MYelofibrosis SECondary to PV and ET) dataset, 135 (10.7%) developed a TE at a median follow-up of 3.5 years (range, 1-21.4), with an incidence of 2.3% patients per year. Venous events accounted for two-thirds of the total. Cox multivariable analysis, supported by Fine-Gray models with death as competitive risk, showed that being on cytoreductive therapy at time of SMF evolution is associated with an absolute risk reduction of thrombosis equal to 3.3% within 3 years. Considering individually cytoreductive therapies, univariate regression model found that both conventional cytoreduction, mainly hydroxyurea, (HR 0.41, 95% CI: 0.26-0.65, p = 0.0001) and JAK inhibitors, mostly ruxolitinib, (HR 0.50, 95% CI: 0.24-1.02, p = 0.05) were associated with fewer thrombosis. Our study informs treating physicians of a non-low incidence of TEs in post PV/ET-MF and of the potential protective role of cytoreductive therapy in terms of thrombotic events., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2022
Full Text
View/download PDF

14. Second versus first wave of COVID-19 in patients with MPN.

Author

Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nałęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, and Vannucchi AM

Subjects
COVID-19 mortality, COVID-19 virology, Humans, Risk Factors, SARS-CoV-2 isolation & purification, Survival Analysis, COVID-19 complications, Myeloproliferative Disorders complications
Published
2022
Full Text
View/download PDF

15. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.

Author

Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marín F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M, Bonifacio M, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC, Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, Vianelli N, Doyle A, Gupta V, Wille K, Tremblay D, and Mascarenhas J

Subjects
Administration, Oral, Atrial Fibrillation etiology, Atrial Fibrillation pathology, Humans, International Agencies, Venous Thromboembolism etiology, Venous Thromboembolism pathology, Anticoagulants administration & dosage, Atrial Fibrillation drug therapy, Myeloproliferative Disorders complications, Venous Thromboembolism drug therapy
Published
2021
Full Text
View/download PDF

16. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.

Author

Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, and Rambaldi A

Subjects
Aged, COVID-19 complications, COVID-19 transmission, COVID-19 virology, Europe epidemiology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myeloproliferative Disorders drug therapy, Myeloproliferative Disorders epidemiology, Myeloproliferative Disorders virology, Nitriles, Prognosis, Pyrimidines, Retrospective Studies, Survival Rate, COVID-19 mortality, Myeloproliferative Disorders mortality, Pyrazoles administration & dosage, SARS-CoV-2 isolation & purification, Withholding Treatment statistics & numerical data
Abstract

We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19.

Published
2021
Full Text
View/download PDF

17. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.

Author

Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, and Finazzi G

Subjects
Case-Control Studies, Humans, Hydroxyurea adverse effects, Nitriles, Pipobroman adverse effects, Polycythemia Vera genetics, Pyrazoles adverse effects, Pyrimidines, Thrombocythemia, Essential genetics, Antineoplastic Agents adverse effects, Neoplasms, Second Primary chemically induced, Philadelphia Chromosome, Polycythemia Vera drug therapy, Primary Myelofibrosis drug therapy, Thrombocythemia, Essential drug therapy
Abstract

We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs. Patients exposed to hydroxyurea (HU) (median: 3 years) had a risk of SC similar to unexposed patients (OR = 1.06, 95% CI 0.82-1.38). In contrast, in cancer-specific stratified multivariable analysis, HU had two-fold higher risk of non-melanoma (NM) skin cancer (OR = 2.28, 95% CI 1.15-4.51). A significantly higher risk of NM-skin cancer was also documented for pipobroman (OR = 3.74, 95% CI 1.00-14.01), ruxolitinib (OR = 3.87, 95% CI 1.18-12.75), and for drug combination (OR = 3.47, 95% CI 1.55-7.75). These three drugs did not show excess risk of carcinoma and hematological second cancer compared with unexposed patients. Exposure to interferon, busulfan, and anagrelide did not increase the risk. In summary, while it is reassuring that no excess of carcinoma was documented, a careful dermatologic active surveillance before and during the course of treatments is recommended.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results